Financial Performance - The company's revenue for Q3 2024 reached ¥450,121,762.05, representing a 55.68% increase year-over-year[2] - Net profit attributable to shareholders was ¥88,673,866.69, up 49.91% compared to the same period last year[2] - The basic earnings per share (EPS) increased by 46.67% to ¥0.22 for Q3 2024[2] - Total revenue for the third quarter reached ¥1,156,571,221.99, an increase of 10.8% compared to ¥1,043,298,697.55 in the same period last year[16] - The net profit for Q3 2024 is CNY 257,849,211.82, a decrease of 14.0% compared to CNY 300,071,378.71 in Q3 2023[17] - The total profit for Q3 2024 is CNY 289,225,864.68, down from CNY 334,621,662.96 in Q3 2023, reflecting a decrease of 13.5%[17] - The total comprehensive income for Q3 2024 is CNY 296,798,635.92, compared to CNY 285,890,455.63 in Q3 2023, reflecting an increase of 3.2%[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥3,776,064,623.64, reflecting a 7.17% increase from the end of the previous year[2] - The company's total liabilities increased to ¥387,951,591.55 from ¥340,982,554.64, indicating a rise of 13.7%[15] - Cash and cash equivalents decreased to ¥1,397,257,372.86 from ¥1,708,241,239.10, a decline of 18.2%[14] - Inventory levels decreased to ¥351,517,731.83 from ¥374,743,251.45, a reduction of 6.2%[14] - The company's equity attributable to shareholders increased to ¥3,388,113,032.09 from ¥3,182,287,615.40, a growth of 6.5%[15] Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥301,736,908.98, showing a 12.41% increase compared to the previous year[2] - Cash flow from operating activities for Q3 2024 is CNY 301,736,908.98, an increase of 12.4% from CNY 268,428,729.92 in Q3 2023[19] - Cash inflow from investment activities in Q3 2024 is CNY 3,548,516,470.60, compared to CNY 2,579,644,558.12 in Q3 2023, indicating a significant increase of 37.6%[20] - The net cash flow from investment activities for Q3 2024 is -CNY 227,209,630.54, worsening from -CNY 61,140,353.45 in Q3 2023[20] - The cash and cash equivalents at the end of Q3 2024 amount to CNY 1,142,159,515.93, slightly up from CNY 1,124,089,840.87 at the end of Q3 2023[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,058, with the largest shareholder, Xiong Xiaochuan, holding 45.74% (186,000,000 shares) of the company[6] - Shenzhen Meitai United Industrial Co., Ltd. holds 7.62% (31,000,000 shares), while Shenzhen Meichuang United Investment Partnership holds 7.24% (29,450,000 shares) and Shenzhen Meichuang Yintai Industrial Partnership holds 6.33% (25,730,000 shares)[6] - The report indicates that there are no changes in the number of shares held by the top 10 shareholders due to margin trading activities[9] - The top 10 unrestricted shareholders include Ningbo Gongcheng Yongyi Investment Partnership with 15,654,300 shares (3.85%) and Xianglu Equity Investment Management with 7,044,528 shares (1.73%)[8] - The company has not disclosed any other relationships among the top shareholders or whether they are considered acting in concert under the regulations[9] - The total number of preferred shareholders and the situation of the top 10 preferred shareholders is not applicable[10] - The company has not reported any changes in restricted shares during the period[10] - The report does not indicate any participation of the top shareholders in margin trading activities[9] Investment and Management - The company plans to invest up to $80 million in building a new production base in Malaysia to enhance its global competitiveness and service capabilities[11] - The company appointed Yan Jun'e as the new Vice General Manager and CFO, effective from August 20, 2024[12] Expenses - Operating costs for the quarter were ¥878,898,846.47, up from ¥730,741,849.53, reflecting a rise of 20.2% year-over-year[16] - Research and development expenses increased to ¥103,341,218.61, compared to ¥79,882,546.84 in the previous year, marking a growth of 29.4%[16] - The company reported a significant increase in accounts receivable, which rose to ¥323,220,509.89 from ¥213,425,277.00, an increase of 51.5%[14] - The company experienced a 62.97% decrease in notes payable, amounting to ¥10,009,959.12, as settlement notes for construction projects matured[5] - The company reported a 335.91% increase in taxes payable, indicating higher corporate income tax and VAT obligations[5] - The company’s investment income decreased by 49.23% to ¥6,526,682.47, attributed to reduced cash management returns[5]
美好医疗(301363) - 2024 Q3 - 季度财报